Harvard Heart Letter

No heart risk-or benefit-from diabetes drug Onglyza

In the largest and most comprehensive study of the heart effects of a diabetes drug, the blood sugar-lowering drug saxagliptin (Onglyza) showed no benefit in protecting against heart disease or stroke. Importantly, the drug also did not increase cardiovas
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »